Inside Diagnostics Live webinar: Best Practice for Biopsy in NSCLC

Epidermal growth factor receptor (EGFR) T790M testing is of recognized clinical relevance for selecting non-small cell lung cancer (NSCLC) patients who are likely to respond to third-generation tyrosine kinase inhibitors (TKIs). However, as many pulmonologists and oncologists can confirm, several questions may emerge around the complex process of obtaining samples for T790M testing:

  • What are the opportunities and challenges of tissue testing at progression?
  • What types of samples can be collected?
  • What biopsy techniques can be used?
  • What is the optimal timing for tissue testing?

To help address these questions, AZ enthusiastically invites you to a 1.5-hour live-streamed webinar entitled “Best Practice for Biopsy in NSCLC” on November 23rd, 2017 at 16.00h GMT. Presented by Dr Neal Navani MD, MSc, PhD, FRCP (University College London Hospital) and Prof. David Baldwin MD, FRCP (Nottingham University Hospital NHS Trust), this seminar will discuss the challenges and recommendations available for obtaining tissue in NSCLC patients. In doing so, the experts will present the clinical relevance of mutation testing, a comprehensive review of biopsy techniques, optimal timing proposals, and a real-world footage and commentary of an EBUS-guided biopsy.

You can register to this webinar using the following link: http://www.workcast.com/register?cpak=2323552099416502

Feel free to submit your questions for the Q&A session of the webinar to info@indigomedical.co.uk.

Best Practice for Biopsy in NSCLC
Best Practice for Biopsy in NSCLC

 

Rudy Hovelinck
Diagnostics Manager at AstraZeneca

 

NS ID BE-1389-RD11/2017-LB

Other Inside Diagnostic Articles

About the Author

Rudy Hovelinck

Diagnostics Manager AstraZeneca

rudy.hovelinck@astrazeneca.com

M. +32 (0) 476 22 58

Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.